α-PHP

Uncontrolled hypertension, Coronary artery disease, Heart failure, Arrhythmias

Pre-existing cardiovascular conditions including uncontrolled hypertension, coronary artery disease, heart failure, and arrhythmias represent absolute contraindications. Tachycardia, hypertension, and thoracic pain are documented in clinical case series (Grapp et al. 2023; Bassi et al. 2025 Pavia Poison Control Centre data). The sympathomimetic mechanism directly produces cardiovascular strain.

Synthetic cathinones as a class reduce seizure threshold (Daziani et al. 2023). Individuals with epilepsy or other seizure predisposition face elevated risk of provoked seizures with α-PHP use.

Visual and auditory hallucinations, paranoid ideation, and delirium are documented in clinical cases of α-PHP exposure (Grapp et al. 2023; Bassi et al. 2025). Pre-existing psychotic disorders are expected to be exacerbated by the compound's potent dopaminergic activation.

Potent dopaminergic and noradrenergic stimulation from α-PHP may precipitate manic episodes in individuals with bipolar disorder. This risk is established for the stimulant class broadly but has not been directly studied for α-PHP.

α-PHP undergoes extensive hepatic biotransformation with 19 Phase I and 9 Phase II metabolites identified (Dinis et al. 2024). Impaired hepatic function could alter metabolite profiles, potentially increasing exposure to genotoxic metabolites (Lenzi et al. 2021 demonstrated metabolite-mediated mutagenicity) and prolonging parent compound exposure.

No renal excretion data have been published for α-PHP. Given the extensive metabolite profile and unknown renal clearance fraction, impaired renal function may prolong exposure to active or toxic metabolites.

A case report documents fetal death associated with maternal use of both MDPHP and α-PHP (Adamowicz & Hydzik 2019). Polydrug exposure prevents definitive attribution, but the case constitutes a reproductive safety signal. Neonatal exposure confirmed via meconium in two additional cases (Grapp et al. 2023). Potent sympathomimetic stimulation poses intrinsic risk to fetal hemodynamics regardless of sole causation.

No direct data on breast milk excretion. However, neonatal meconium confirmation of α-PHP (Grapp et al. 2023) demonstrates transplacental transfer, and the compound's lipophilicity (low aqueous solubility, hexyl chain) suggests excretion in breast milk is likely. Neonatal exposure to a potent sympathomimetic stimulant is unacceptable.

Co-administration of α-PHP with irreversible MAOIs (phenelzine, tranylcypromine) or reversible MAOIs (moclobemide) risks life-threatening hypersympathomimetic crisis. DAT/NET blockade combined with impaired monoamine catabolism results in dangerous catecholamine accumulation in the synaptic cleft. This interaction is firmly established for the DAT/NET-blocker mechanism class but has not been directly studied for α-PHP.